News By Tag Industry News News By Place Country(s) Industry News
|  Recent Study: Product Profiles: Autism Spectrum Disorders - Growing interest in underserved marketNew Healthcare market report from Datamonitor: "Product Profiles: Autism Spectrum Disorders - Growing interest in underserved market"
By: Fast Market Research, Inc. Report Scope * Overview of marketed and pipeline drugs in clinical development for autism spectrum disorders. * Analysis of the market positioning of each product approved for the treatment of autism spectrum disorders. * Assessment of the strengths, weaknesses, opportunities, and threats for marketed and late-stage pipeline candidates. * Summary of the clinical and commercial attractiveness for each of the marketed products. * Insight from key opinion leaders on marketed and pipeline products. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Report Highlights Risperdal and Abilify are the only two products approved for the treatment of autism spectrum disorders (ASDs). Both of these atypical antipsychotics are indicated for the management of irritability symptoms associated with ASDs in the US. Due to the failure of these drugs to address the core symptoms of ASDs, many other drugs are used off-label. Abilify is the most recent entrant to the ASDs market, having received US Food and Drug Administration (FDA) approval in November 2009. The drug's partial agonism of dopamine receptors unique mechanism of action is considered a key differentiating factor, producing a superior side-effect profile compared to other atypical antipsychotics. To date, none of the four late-stage pipeline candidates for autism spectrum disorders has publically presented the late-stage Phase II or Phase III trial data necessary for the clinical assessment of these compounds Reasons to Get this Report * What are the key differentiating features of approved therapies for the treatment of autism spectrum disorders? * How do key opinion leaders perceive available treatments for autism spectrum disorders? * What opportunities are there for existing players in the autism spectrum disorders market to increase their market share? * What is the development status of current pipeline candidates? * What clinical trial designs are current pipeline candidates following? What do pipeline candidates need to demonstrate in order to be successful? Partial Table of Contents: OVERVIEW * Catalyst * Summary EXECUTIVE SUMMARY * Update details: April 2012 * Strategic scoping and focus * Datamonitor key findings * Related reports MARKET DEFINITION AND OVERVIEW * Market definition * Product overview MARKETED PRODUCT PROFILES * Abilify (aripiprazole; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Risperdal (risperidone; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness PIPELINE PRODUCT PROFILES * CM-AT (Curemark) * Drug profile * Development overview * SWOT analysis * AT001 (fluoxetine; * Drug profile * Development overview * SWOT analysis * Other drugs in clinical development for autism spectrum disorders * STX-209 (arbaclofen; * Memantine hydrochloride (Forest Laboratories/ * UCB-MNC (umbilical cord blood mononuclear stem cells; Beike Biotech) * Carbetocin (Kyalin Bioscience) * RG-7314 (Roche) * RO-5028442 (Roche) BIBLIOGRAPHY * Journal papers * Websites * Datamonitor reports APPENDIX * PharmaVitae Explorer database * Contributing experts * Conferences attended * Report methodology TABLES * Table: Summary of therapeutic classes in autism spectrum disorders by A natomical Therapeutic Chemical code, 2012 * Table: Summary of the ICD-10 codes used to derive drugs indicated and in clinical development for autism spectrum disorders * Table: Key marketed products for autism spectrum disorders, June 2012 * Table: Key pipeline products for autism spectrum disorders, April 2012 * Table: Abilify (aripiprazole; * Table: Overview of pivotal and long-term trials conducted for Abilify (aripiprazole) * Table: Overview of side effects associated with Abilify in two pivotal Phase III clinical trials in autism spectrum disorders * Table: Datamonitor drug assessment summary of Abilify (aripiprazole; * Table: Risperdal (risperidone; * Table: Overview of pivotal trials conducted for Risperdal in the treatment of autism spectrum disorders * Table: Overview of side effects reported in two pivotal Phase III clinical trials of Risperdal in autism spectrum disorders * Table: Datamonitor drug assessment summary of Risperdal (risperidone; * Table: CM-AT (Curemark) - drug profile, 2012 * Table: Phase III clinical trial of CM-AT in the treatment of core symptoms of autism spectrum disorders, 2012 * Table: Phase III open-label extension study of CM-AT in the treatment of core symptoms of autism spectrum disorders, 2012 * Full Table of Contents is available at: -- http://www.fastmr.com/ About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number